Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 28;15(3):656.
doi: 10.3390/v15030656.

Virological Markers in Epstein-Barr Virus-Associated Diseases

Julien Lupo  1   2 , Aurélie Truffot  1   2 , Julien Andreani  1   2 , Mohammed Habib  1 , Olivier Epaulard  1   3 , Patrice Morand  1   2 , Raphaële Germi  1   2
Affiliations
Review

Virological Markers in Epstein-Barr Virus-Associated Diseases

Julien Lupo et al. Viruses. .

Abstract

Epstein-Barr virus (EBV) is an oncogenic virus infecting more than 95% of the world's population. After primary infection-responsible for infectious mononucleosis in young adults-the virus persists lifelong in the infected host, especially in memory B cells. Viral persistence is usually without clinical consequences, although it can lead to EBV-associated cancers such as lymphoma or carcinoma. Recent reports also suggest a link between EBV infection and multiple sclerosis. In the absence of vaccines, research efforts have focused on virological markers applicable in clinical practice for the management of patients with EBV-associated diseases. Nasopharyngeal carcinoma is an EBV-associated malignancy for which serological and molecular markers are widely used in clinical practice. Measuring blood EBV DNA load is additionally, useful for preventing lymphoproliferative disorders in transplant patients, with this marker also being explored in various other EBV-associated lymphomas. New technologies based on next-generation sequencing offer the opportunity to explore other biomarkers such as the EBV DNA methylome, strain diversity, or viral miRNA. Here, we review the clinical utility of different virological markers in EBV-associated diseases. Indeed, evaluating existing or new markers in EBV-associated malignancies or immune-mediated inflammatory diseases triggered by EBV infection continues to be a challenge.

Keywords: EBV DNA; Epstein–Barr virus; biomarkers; infectious mononucleosis; lymphoma; multiple sclerosis; nasopharyngeal carcinoma; post-transplant lymphoproliferative disorders; serology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Evolution of antibody and blood EBV DNA markers during EBV infection in an immunocompetent host.
See this image and copyright information in PMC

References

    1. Baer R., Bankier A.T., Biggin M.D., Deininger P.L., Farrell P.J., Gibson T.J., Hatfull G., Hudson G.S., Satchwell S.C., Séguin C., et al. DNA sequence and expression of the B95-8 Epstein—Barr virus genome. Nature. 1984;310:207–211. doi: 10.1038/310207a0. - DOI - PubMed
    1. Epstein M., Achong B., Barr Y. Virus particles in cultured lymphoblasts from burkitt’s lymphoma. Lancet. 1964;1:702–703. doi: 10.1016/S0140-6736(64)91524-7. - DOI - PubMed
    1. Münz C. Latency and lytic replication in Epstein–Barr virus-associated oncogenesis. Nat. Rev. Genet. 2019;17:691–700. doi: 10.1038/s41579-019-0249-7. - DOI - PubMed
    1. Young L.S., Yap L.F., Murray P.G. Epstein–Barr virus: More than 50 years old and still providing surprises. Nat. Rev. Cancer. 2016;16:789–802. doi: 10.1038/nrc.2016.92. - DOI - PubMed
    1. Farrell P.J. Epstein-Barr Virus and Cancer. Annu. Rev. Pathol. Mech. Dis. 2019;14:29–53. doi: 10.1146/annurev-pathmechdis-012418-013023. - DOI - PubMed